share_log

T2 Biosystems | 8-K: T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems | 8-K: T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems | 8-K：T2 Biosystems 公布2024年第三季度财务业绩
美股SEC公告 ·  2024/11/15 22:59

Moomoo AI 已提取核心信息

T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, announced its financial results for the third quarter ended September 30, 2024. The company reported a 34% increase in total revenue, reaching $2.0 million, compared to the same period in the previous year. This growth was primarily driven by a 34% rise in sepsis test panel revenue, largely due to increased U.S. sales of the T2Bacteria Panel. T2 Biosystems also executed contracts for 11 T2Dx Instruments, expanded its U.S. market access through an exclusive distribution agreement with Cardinal Health, and launched a co-marketing collaboration with Prxcision, Inc. Additionally, the company received FDA clearance to market the T2Candida Panel for pediatric patients and is advancing the T2Resistance Panel towards FDA 510(k) submission, expected in the first quarter of 2025. Despite these advancements, the company reported a net loss of $10.1 million, or $(0.57) per share, for the quarter. As of September 30, 2024, T2 Biosystems had cash and cash equivalents of $2.1 million and raised $4.3 million in net proceeds through an ATM during the quarter.
T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, announced its financial results for the third quarter ended September 30, 2024. The company reported a 34% increase in total revenue, reaching $2.0 million, compared to the same period in the previous year. This growth was primarily driven by a 34% rise in sepsis test panel revenue, largely due to increased U.S. sales of the T2Bacteria Panel. T2 Biosystems also executed contracts for 11 T2Dx Instruments, expanded its U.S. market access through an exclusive distribution agreement with Cardinal Health, and launched a co-marketing collaboration with Prxcision, Inc. Additionally, the company received FDA clearance to market the T2Candida Panel for pediatric patients and is advancing the T2Resistance Panel towards FDA 510(k) submission, expected in the first quarter of 2025. Despite these advancements, the company reported a net loss of $10.1 million, or $(0.57) per share, for the quarter. As of September 30, 2024, T2 Biosystems had cash and cash equivalents of $2.1 million and raised $4.3 million in net proceeds through an ATM during the quarter.
t2 biosystems，一家在快速检测导致败血症的病原体方面处于领先地位的公司，宣布截至2024年9月30日的第三季度财务业绩。该公司报告总营业收入增长34%，达到200万美元，与去年同期相比。这一增长主要是由败血症检测试剂盒营业收入增长34%推动的，这在很大程度上是由于T2Bacteria Panel在美国销售增加。 t2 biosystems还与卡地纳健康签订了11份T2Dx仪器合同，通过与Cardinal Health达成独家分销协议扩大了其在美国市场的准入，并与Prxcision, Inc.展开共同营销合作。此外，该公司获得FDA批准在儿童患者中销售T2Candida Panel，...展开全部
t2 biosystems，一家在快速检测导致败血症的病原体方面处于领先地位的公司，宣布截至2024年9月30日的第三季度财务业绩。该公司报告总营业收入增长34%，达到200万美元，与去年同期相比。这一增长主要是由败血症检测试剂盒营业收入增长34%推动的，这在很大程度上是由于T2Bacteria Panel在美国销售增加。 t2 biosystems还与卡地纳健康签订了11份T2Dx仪器合同，通过与Cardinal Health达成独家分销协议扩大了其在美国市场的准入，并与Prxcision, Inc.展开共同营销合作。此外，该公司获得FDA批准在儿童患者中销售T2Candida Panel，并正在推进T2Resistance Panel向FDA 510(k)提交，预计将于2025年第一季度提交。尽管取得这些进展，该公司报告第一季度每股亏损1010万美元，每股亏损0.57美元。截至2024年9月30日，t2 biosystems的现金及现金等价物为210万美元，并在该季度通过ATm筹集了净收益430万美元。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间